Princeton Capital Management LLC lessened its position in Merck & Co., Inc. (NYSE:MRK) by 3.2% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 6,214 shares of the company’s stock after selling 208 shares during the quarter. Princeton Capital Management LLC’s holdings in Merck & Co., Inc. were worth $479,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also recently made changes to their positions in MRK. OLD Mission Capital LLC bought a new position in Merck & Co., Inc. in the 3rd quarter worth $247,000. Sage Mountain Advisors LLC bought a new position in shares of Merck & Co., Inc. during the 4th quarter worth about $432,000. Ironwood Wealth Management LLC. increased its holdings in shares of Merck & Co., Inc. by 1,175.3% during the 4th quarter. Ironwood Wealth Management LLC. now owns 5,050 shares of the company’s stock worth $413,000 after purchasing an additional 4,654 shares during the period. Almanack Investment Partners LLC. increased its holdings in shares of Merck & Co., Inc. by 48.8% during the 4th quarter. Almanack Investment Partners LLC. now owns 7,902 shares of the company’s stock worth $651,000 after purchasing an additional 2,591 shares during the period. Finally, Cambiar Investors LLC bought a new position in shares of Merck & Co., Inc. during the 4th quarter worth about $281,000. Hedge funds and other institutional investors own 71.98% of the company’s stock.
Several research analysts have recently issued reports on MRK shares. SVB Leerink dropped their price objective on shares of Merck & Co., Inc. from $102.00 to $99.00 and set an “outperform” rating on the stock in a report on Thursday, June 3rd. JPMorgan Chase & Co. dropped their price objective on shares of Merck & Co., Inc. from $105.00 to $100.00 and set an “overweight” rating on the stock in a report on Wednesday. Truist Securities decreased their target price on shares of Merck & Co., Inc. from $96.00 to $93.00 and set a “buy” rating on the stock in a research report on Monday. Finally, Argus restated a “hold” rating on shares of Merck & Co., Inc. in a research report on Thursday, May 20th. Three investment analysts have rated the stock with a hold rating and nine have given a buy rating to the stock. Merck & Co., Inc. presently has a consensus rating of “Buy” and an average target price of $96.11.
Shares of MRK traded down $0.27 on Friday, reaching $75.87. 507,239 shares of the company’s stock were exchanged, compared to its average volume of 11,922,932. The company has a debt-to-equity ratio of 0.89, a current ratio of 1.02 and a quick ratio of 0.78. The stock has a market cap of $192.11 billion, a PE ratio of 27.59, a P/E/G ratio of 1.84 and a beta of 0.40. The stock’s 50 day simple moving average is $76.85. Merck & Co., Inc. has a 12 month low of $71.71 and a 12 month high of $87.80.
Merck & Co., Inc. (NYSE:MRK) last posted its quarterly earnings results on Thursday, April 29th. The company reported $1.40 earnings per share for the quarter, missing the Zacks’ consensus estimate of $1.63 by ($0.23). Merck & Co., Inc. had a return on equity of 54.15% and a net margin of 14.64%. The business had revenue of $12.08 billion for the quarter, compared to the consensus estimate of $12.71 billion. During the same period last year, the firm earned $1.50 earnings per share. The company’s quarterly revenue was up .2% on a year-over-year basis. As a group, equities analysts forecast that Merck & Co., Inc. will post 6.47 EPS for the current fiscal year.
The company also recently announced a dividend, which was paid on Wednesday, June 2nd. Shareholders of record on Friday, June 4th were paid a $0.65 dividend. This represents a yield of 3.42%. The ex-dividend date of this dividend was Thursday, June 3rd. Merck & Co., Inc.’s payout ratio is presently 43.77%.
About Merck & Co., Inc.
Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health segments. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, diabetes, and women's health, as well as vaccine products.
Featured Story: Diversification Important in Investing
Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRK).
Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.